Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip
NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Biochip Markets: Microarrays and Lab-on-a-Chip
http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html
INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC's goal for this study was to determine the status of current and emerging biochip technologies and products, and assess their worldwide growth potential over a 5-year period from 2009 to 2014. We were particularly interested in characterizing the biochip markets for single nucleotide polymorphisms (SNPs), epigenetics, array comparative genome hybridization (aCGH), microRNA (miRNA), proteomics microarray, and lab-on-a-chip (LOAC) markets, which will provide substantial future growth opportunities for biochips. A particular focus of this study is the market for biochip-based diagnostics products.
Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biochip technologies and the current and future commercial potential for each of the key market segments.
REASONS FOR DOING THE STUDY
Biology is following a path that is reminiscent of the early electronics industry: a miniaturization and large-scale integration process that will revolutionize life-science research, drug discovery and development, medical diagnostics and biotechnology. The ongoing miniaturization and large-scale integration process is encompassed in devices known as biochips, including microarrays and LOAC microfluidic devices. Biochips represent a diverse group of nanotechnologies that can be expected to exert a significant impact in life-science research, diagnostics, and medicine.
DNA microarrays are already an established technology generating substantial revenue derived from gene expression, SNP analysis and gene resequencing. Several biochip-based diagnostics have been launched in the past few years, including some that have been approved by the FDA for in vitro diagnostic (IVD) applications. We foresee significant market growth in biochips as diagnostics. Protein microarrays are gaining prominence in the marketplace, while future, emerging array technologies, including tissue/cell and glycomics arrays, are increasing in importance. LOAC devices are also making rapid progress in important pharmaceutical and diagnostics market segments.
BCC previously examined the biochip industry in 2007. Given the rapidly advancing bio- and nanotechnologies associated with this business, and the changing industry dynamics, it is timely to reexamine the biochips business.
INTENDED AUDIENCE
We have compiled a study of critical biochip technologies that will be important in the four major end-user segments. We present the biochip technologies and growth driving forces, product types, key market applications, companies, and alliances, future market potential and product sales forecasts for the period 2009 through 2014. We project the future use of microarray and LOAC products for the key end-use segments: research tools, drug discovery and development, diagnostics, next-generation sequencing, biodefense, food testing, and forensics.
This study will be of particular interest to the companies in the following industries: diagnostics, pharmaceuticals, biotechnology, nanotechnology, life-sciences tools, biodefense, medical devices, polymers, glass, bioinformatics, and genetic services. It will also be of interest to companies involved in drug and/or biomarker discovery programs, manufacturers of microarrays and LOAC devices, antibodies, restriction enzymes or primers, bioinformatics developers, and cancer researchers and clinicians.
SCOPE OF REPORT
The study scope includes the major biochip technologies that are likely to become commercialized within the next 5 years. Each technology is analyzed to determine its market status, impact on future market segments, and forecast growth from 2009 through 2014. Technology issues and market driving forces are discussed. Influencing factors including large-scale integration, microfluidics, nanotechnology, large-scale biochip, genomic and proteomic research initiatives, cancer diagnostic and treatment trends, and drug discovery and development needs are discussed.
BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug discovery and development, diagnostics, next-generation DNA sequencing, biodefense, food safety, and forensics.
Based on our analysis, we evaluate the potential applications of biochips in each of the major market segments, and forecast sales revenues for 2009 through 2014.
BCC examines biochip companies and industry alliances, and the impact of large-scale biochip-related projects on the market growth. We also examine patent strategies within the industry. A total of 143 companies are profiled.
METHODOLOGY
Both primary and secondary research methodologies were used in this market study. For research tools and drug discovery and development, the study presents a forecast from 2009 through 2014 for each of the important products and technologies. For DNA microarrays, the study forecasts market size by application and analysis type. For diagnostics, the report forecasts from 2009 through 2014 the demand for biochips by chip type and by indication, as well as cancer biochips by type and application. This study forecasts from 2009 through 2014 the market for LOAC devices by end-use market and by application. The geographical markets are forecast for each biochip type.
INFORMATION SOURCES
BCC surveyed life-science companies and research institutions to obtain data for this study. Included were research tools firms, diagnostics firms, drug firms, microarray and LOAC companies, and leading microarray research institutions. We also spoke with users of in vitro personalized medicine devices. In addition, we compiled data from secondary sources, including industry, trade, and government.
ANALYST CREDENTIALS
The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; Biologic Imaging Reagents: Future Technologies and Markets and Synthetic Biology. Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.
THIS REPORT:
The total market for biochips was $2.4 billion in 2008 which increased to $2.6 billion in 2009. This is expected to grow at compound annual growth rate (CAGR) of 17.7% to reach $5.9 billion by 2014
The DNA microarrays market was nearly $1.2 billion in 2008; this further increased to $1.3 billion in 2009, this projected to reach $2.7 billion in 2014, for a 5-year CAGR of 15.2%.
Sales in the LOAC market amounted to $755 million in 2008 which increased to $817 million in 2009. This is projected to increase to $2.1 billion in 2014, for a 5-year CAGR of 20.9%.
Chapter- 1: INTRODUCTION -- Complimentary
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE OF REPORT 2
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 4
BCC ONLINE SERVICES 4
DISCLAIMER 4
Chapter-2: SUMMARY
SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 5
SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, 2007-2014 ($ MILLIONS) 6
SUMMARY (CONTINUED) 7
Chapter-3: OVERVIEW
INTRODUCTION 8
INTRODUCTION (CONTINUED) 9
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 10
FIGURE 1 EVOLUTION OF BIOCHIPS 10
INTRODUCTION (CONTINUED) 11
BIOCHIP TYPES 12
FIGURE 2 CLASSIFICATION OF BIOCHIPS 12
TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES 13
BIOCHIP TYPES (CONTINUED) 14
TABLE 3 BIOCHIP NOMENCLATURE 15
BIOCHIP TECHNOLOGIES COVERED IN THIS REPORT 16
TABLE 4 SCOPE OF THIS REPORT 16
WHAT IS NEW IN THIS REPORT 16
MARKET POTENTIAL OF BIOCHIPS 17
TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 18
TABLE 6 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS) 18
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS 19
TABLE 7 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH 20
DRIVING FORCES FOR … (CONTINUED) 21
BIOCHIPS: A CONVERGENCE OF DIVERSE TECHNOLOGIES 22
TABLE 8 MULTIDISCIPLINARY FIELD OF BIOCHIPS 22
LIFE CYCLE STATUS OF BIOCHIP PRODUCTS 23
TABLE 9 LIFE CYCLE STATUS OF BIOCHIP TYPES 23
COMMERCIAL STATUS OF BIOCHIPS 24
MICROARRAYS 24
LOAC 25
THE BIOCHIP INDUSTRY 25
TABLE 10 BIOCHIP INDUSTRY KEY COMPETITORS 25
THE BIOCHIP INDUSTRY (CONTINUED) 26
Chapter-4: MICROARRAY TECHNOLOGIES
INTRODUCTION 27
THE NANOSCALE WORLD 27
TABLE 11 THE NANOSCALE WORLD 27
TABLE 12 MICROARRAY TYPES 28
TABLE 13 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 28
The Nanoscale World (Continued) 29
DNA MICROARRAY TECHNOLOGIES 30
INTRODUCTION 30
FIGURE 3 MICROARRAY FEATURE DENSITY 30
FIGURE 4 MICROARRAY RESOLUTION 31
TABLE 14 MICROARRAY GENOME CONTENT 31
TABLE 15 DNA MICROARRAY PLATFORM FEATURES 32
TABLE 16 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 33
TABLE 16 (CONTINUED) 34
Introduction (Continued) 35
STEPS IN THE DNA MICROARRAY EXPERIMENT 36
DNA MICROARRAY APPLICATIONS 36
TABLE 17 DNA MICROARRAY APPLICATIONS 37
Gene Expression Profiling 38
TABLE 18 PROBES FOR GENE EXPRESSION DNA MICROARRAYS 38
Gene Expression Profiling (Continued) 39
TABLE 19 EXAMPLE APPLICATIONS OF GENE EXPRESSION PROFILING 40
FIGURE 5 GENETIC ANALYSIS TECHNOLOGY COMPETITIVE SPACE 41
TABLE 20 GENETIC ANALYSIS TECHNOLOGIES COMPARISON 42
FIGURE 6 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1 43
FIGURE 7 COMPETITIVE SPACE FOR GENE EXPRESSION ANALYSIS 44
FIGURE 8 APPLICATIONS SPACE WITH INTENSE TECHNOLOGY COMPETITION 45
Gene Expression Profiling (Continued) 46
TABLE 21 PLATFORMS FOR HIGH-THROUGHPUT QUANTITATIVE GENE EXPRESSION ANALYSIS 47
TABLE 22 GENE EXPRESSION PLATFORMS OF TWO LEADING DNA ARRAY MANUFACTURERS 47
TABLE 22 (CONTINUED) 48
TABLE 23 PROBE SENSITIVITY AND SPECIFICITY 48
Gene Expression Profiling (Continued) 49
SNP Analysis 50
FIGURE 9 SNP ANALYSIS PLATFORMS 51
Epigenetic Analysis 52
FIGURE 10 EPIGENOMICS WITHIN THE MOLECULAR BIOLOGY PARADIGM 53
DNA Methylation 53
FIGURE 11 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 54
Histones 54
FIGURE 12 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC 55
DNA Methylation and Histone Analysis Workflow 56
FIGURE 13 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS 57
DNA Methylation Microarrays 57
ChIP-on-Chip 58
TABLE 24 CHIP ASSAYS 59
TABLE 25 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES 60
TABLE 26 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS 61
Cytogenetic Analysis 61
TABLE 27 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 62
FIGURE 14 COMPETITIVE SPACE FOR CNV ANALYSIS 63
Cytogenetic Analysis (Continued) 64
TABLE 28 CGH MICROARRAY PROBE PLATFORMS 65
TABLE 29 CGH MICROARRAY TRENDS 66
Cytogenetic Analysis (Continued) 67
TABLE 30 FUTURE TECHNOLOGY NEEDS FOR CGH MICROARRAYS 68
miRNA Analysis 69
TABLE 31 WORKFLOW FOR AN MIRNA EXPERIMENT 70
TABLE 32 TECHNICAL CHALLENGES FOR MIRNAS 71
ARRAYS ON BEADS 72
TABLE 33 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS 72
CATALOG AND CUSTOM DNA MICROARRAYS 72
SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR MICROARRAYS 73
TOXICOGENOMICS 74
DNA SEQUENCING 75
FIGURE 15 COMPARISON OF SANGER WITH UHTS DNA SEQUENCING TECHNOLOGIES 76
TABLE 34 SMS TECHNOLOGY 77
TABLE 35 COMPARISON OF SELECTED DNA SEQUENCING PLATFORMS 78
FIGURE 16 COMPETITIVE SPACE FOR HIGH-THROUGHPUT GENOMIC ANALYSIS 79
TABLE 36 BIOCHIP CONTENT IN NHGRI GRANTEES FOR NEXT-GENERATION DNA SEQUENCING, 2005 80
TABLE 36 (CONTINUED) 81
TABLE 37 NEXT-GENERATION DNA SEQUENCING COMPANIES 82
RESEQUENCING APPROACHES IN DIAGNOSTICS 82
DNA MICROARRAY MANUFACTURING 83
FIGURE 17 DNA MICROARRAY MANUFACTURING TECHNOLOGIES 83
DNA Microarray Manufacturing (Continued) 84
TABLE 38 DNA MICROARRAY PROBE DENSITY TRENDS, FEATURES PER CHIP, 1996–2009 85
DNA MICROARRAY TECHNOLOGY TRENDS 85
DNA MICROARRAY TECHNOLOGY CHALLENGES 86
FIGURE 18 DNA MICROARRAY COST-VOLUME CURVE 87
PROTEIN MICROARRAY TECHNOLOGIES 88
INTRODUCTION 88
FIGURE 19 IMPORTANCE OF PROTEINS 88
PROTEOMICS WORKFLOW 89
FIGURE 20 PROTEIN ANALYSIS APPROACHES CONTRASTED 89
PROTEIN MICROARRAY DESIGN FEATURES 90
TABLE 39 PROTEIN MICROARRAY PLATFORMS 90
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS 91
TABLE 40 PROTEIN MICROARRAYS AS RESEARCH TOOLS 92
PROTEIN MICROARRAY TYPES 93
TABLE 41 PROTEIN MICROARRAY PRODUCT TYPES 93
Protein Microarray Types (Continued) 94
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES 95
TABLE 42 PROTEIN MICROARRAY TECHNICAL CHALLENGES 96
Protein Microarray Technology Challenges (Continued) 97
PROTEIN MICROARRAY TECHNOLOGY TRENDS 98
TABLE 43 PROTEIN MICROARRAY TECHNOLOGY TRENDS 98
EMERGING MICROARRAY TECHNOLOGIES 99
TABLE 44 EMERGING MICROARRAY TECHNOLOGIES 99
GLYCOMICS MICROARRAYS 100
Glycomics Microarrays (Continued) 101
TMAS 102
FCMS 103
TABLE 45 U.S. GOVERNMENT INITIATIVES PROMOTING EMERGING MICROARRAYS 104
MICROARRAY TECHNOLOGY TRENDS 105
TABLE 46 MICROARRAY TECHNOLOGY TRENDS 105
MICROARRAY TECHNOLOGY TRENDS (CONTINUED) 106
Chapter-5: LOAC TECHNOLOGIES
INTRODUCTION 107
TABLE 47 MICROFLUIDICS PRODUCT LIFE CYCLE STAGE 107
TABLE 48 LOAC SUBSTRATE TECHNOLOGIES 108
LOAC TYPES 109
TABLE 49 LOAC TYPES 109
IN VITRO PROTEOMICS 109
ELECTROPHORESIS ON A CHIP 110
STRUCTURAL PROTEOMICS 110
PCR ON A CHIP 111
IMMUNOASSAYS ON A CHIP 112
Immunoassays on a Chip (Continued) 113
TABLE 50 IMMUNOASSAY-ON-A-CHIP APPLICATIONS 114
LOAC APPLICATIONS 114
TABLE 51 LOAC MARKET SEGMENTS 115
TABLE 52 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 116
LOAC KEY TECHNOLOGY TRENDS 116
TABLE 53 LOAC KEY TECHNOLOGY TRENDS 117
TABLE 54 LOAC TECHNOLOGY PLATFORMS 118
LOAC TECHNOLOGY CHALLENGES 119
TABLE 55 LOAC TECHNOLOGY CHALLENGES 120
Chapter-6: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT
BIOCHIP MARKET SEGMENTATION 121
TABLE 56 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS 121
DRUG DISCOVERY AND DEVELOPMENT 122
TABLE 57 DRUG R&D INVESTMENT BY STAGE, 2003 (%) 123
DRUG INDUSTRY CHALLENGES 123
OVERVIEW OF THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 124
FIGURE 21 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE 124
TABLE 58 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 125
TABLE 58 (CONTINUED) 126
DRUG TARGET IDENTIFICATION 127
DRUG DISCOVERY 127
Structural Biology 127
Lead Generation 128
Lead Generation (Continued) 129
Lead Generation (Continued) 130
Lead Optimization 131
Process R&D 132
Preclinical and Clinical Trials 132
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 132
TABLE 59 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 132
TABLE 59 (CONTINUED) 133
Needs in the Drug Discovery and … (Continued) 133
Needs in the Drug Discovery and … (Continued) 134
FIGURE 22 VALIDATION GAP FOR FUTURE DRUG TARGETS (NUMBER OF POTENTIAL DRUG TARGETS) 135
Needs in the Drug Discovery and … (Continued) 136
Chapter-7: BIOCHIP APPLICATIONS IN DIAGNOSTICS
INTRODUCTION 137
DRIVING FORCES FOR ADOPTION OF BIOCHIP DIAGNOSTIC PLATFORMS 137
BIOMARKER DISCOVERY AND VALIDATION 137
CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS 138
TABLE 60 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 139
MICROARRAY STANDARDIZATION EFFORTS 140
Microarray Quality Control Project 140
External RNA Controls Consortium (ERCC) Study 141
Association of Bimolecular Resource Facilities (ABRF) CGH Microarray Platform Study 142
TABLE 61 COMPARISON OF ARRAY-CGH PLATFORMS 142
OVERVIEW OF MDX 143
INTRODUCTION 143
BENEFITS OF BIOCHIPS AS AN MDX PLATFORM 144
Benefits of Biochips as an MDX Platform (Continued) 145
FIGURE 23 BIOCHIPS TARGET HIGH GROWTH, HIGH MARGIN PORTION OF THE IVD MARKET 146
TABLE 62 BIOTECHNOLOGY DRUGS APPROVED BY THE FDA, 1980–2008 (NUMBER) 147
PHARMACOGENOMICS TESTS 147
Pharmacogenomics Tests (Continued) 148
STRATEGIES FOR COMMERCIALIZING PGX TESTS 149
MDX MARKET PENETRATION CHALLENGES 150
TABLE 63 COMPARISON OF DNA-BASED MDX PLATFORMS 151
TABLE 64 FACTORS AFFECTING PENETRATION OF BIOCHIPS INTO THE MDX MARKET 152
MDX Market Penetration Challenges (Continued) 153
MDX MARKET SEGMENTS 154
MDX TEST SENSITIVITY AND SPECIFICITY 155
FIGURE 24 SENSITIVITY AND SPECIFICITY 156
STATUS OF BIOCHIPS DIAGNOSTICS BY INDICATION 157
SUMMARY OF BIOCHIPS DIAGNOSTICS 157
CANCER OVERVIEW 157
TABLE 65 U.S. INCIDENCE AND TREATMENT DECISIONS FOR SELECTED CANCERS, 2009 157
HEMATOLOGICAL CANCERS 158
BLADDER CANCER 158
BREAST CANCER 159
Breast Cancer Screening 159
Prognosis and Pharmacogenetics Tests 160
FIGURE 25 BREAST CANCER TREATMENT DECISION TREE FOR ONCOTYPE DX 161
TABLE 66 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 162
Breast Cancer MDx Platforms 162
TABLE 67 BREAST CANCER MDX TECHNOLOGY PLATFORMS 163
Breast Cancer Multivariate Diagnostic Tests 164
TABLE 68 COMMERCIAL LANDSCAPE FOR MULTIVARIATE BREAST CANCER TESTS, BY PARAMETER 164
TABLE 68 (CONTINUED) 165
Breast Cancer Multivariate … (Continued) 166
Regulatory Status of Gene Profiling Diagnostic Tests 167
TABLE 69 FDA REGULATORY POSITION ON IVDMIA 167
CERVICAL CANCER 168
TABLE 70 COMMERCIAL LANDSCAPE FOR HPV TESTS 168
TABLE 70 (CONTINUED) 169
COLORECTAL CANCER 170
Conventional Colorectal Cancer Screening Tests 170
TABLE 71 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 171
Molecular Colorectal Cancer Diagnostics Tests 172
TABLE 72 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 172
Molecular Colorectal Cancer … (Continued) 173
CUP 174
TABLE 73 COMMERCIAL MDX PLATFORMS FOR TISSUE OF ORIGIN TESTS 175
GASTRIC CANCER 176
LUNG CANCER 177
Lung Cancer (Continued) 178
OVARIAN CANCER 179
TABLE 74 OVARIAN CANCER SCREENING TESTS 179
TABLE 75 OVARIAN CANCER DIAGNOSTIC TEST STATUS 180
PANCREATIC CANCER 180
PEDIATRIC CANCERS 181
PROSTATE CANCER 181
Prostate Cancer (Continued) 182
COMPREHENSIVE CANCER TESTS 183
STATUS OF BIOCHIP-BASED INFECTIOUS DISEASE DIAGNOSTICS 183
SEPSIS 183
TUBERCULOSIS 184
MRSA 184
INFLUENZA 185
OTHER INFECTIOUS DISEASES 185
STATUS OF BIOCHIP-BASED DME DIAGNOSTICS 186
DMES 186
TABLE 76 MICROARRAY-BASED DME DIAGNOSTICS TESTS 186
DMEs (Continued) 187
WARFARIN DOSING 188
TABLE 77 WARFARIN CYP PGX DIAGNOSTICS TEST COMPETITOR SPACE 189
TABLE 77 (CONTINUED) 190
Warfarin Dosing (Continued) 191
TABLE 78 CYP450 GENE FAMILY PHARMACOGENETIC DIAGNOSTIC GLOBAL TEST MARKET POTENTIAL, 2009 ($ MILLIONS) 192
STATUS OF BIOCHIP-BASED NEUROLOGICAL DIAGNOSTICS 192
ALZHEIMERS DISEASE 192
SCHIZOPHRENIA 193
STATUS OF BIOCHIP-BASED HEART DISEASE DIAGNOSTICS 193
CHF FAILURE 193
TABLE 79 BNP MDX TESTS FOR CHF 194
CHF Failure (Continued) 195
OTHER CARDIAC DIAGNOSTICS 196
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR CF 197
TABLE 80 CF BIOCHIP DIAGNOSTIC PLATFORMS 197
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR PRE- AND POST-NATAL 198
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR IMMUNE DISEASES 199
HLA TYPING TESTS 199
AUTOIMMUNE TESTING 200
STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR FOOD SAFETY/QC 201
TABLE 81 BIOCHIPS STATUS IN FOOD SAFETY/QC MARKET 201
STATUS OF BIOCHIP- … (CONTINUED) 202
Chapter-8: BIOCHIP MARKET GROWTH DRIVING FORCES
INTRODUCTION 203
FIGURE 26 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO MICROARRAYS AND LAB ON A CHIP, 2000–2009 (NUMBER OF PUBMED CITATIONS) 203
FIGURE 26 (CONTINUED) 204
BIOCHIP GROWTH DRIVING FORCES 204
TABLE 82 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH 205
FUNDING FOR LIFE SCIENCE RESEARCH 205
TABLE 83 STIMULUS FUNDING ALLOCATED TO U.S. SCIENCE SPENDING, 2009 ($ MILLIONS) 206
FIGURE 27 NIH ANNUAL FUNDING BUDGET, 2000–2009 ($ BILLIONS) 206
LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP INITIATIVES 207
TABLE 84 RESEARCH INITIATIVES DRIVING BIOCHIP GROWTH, 1999–2008 208
Large-scale Genomic, Proteomic, … (continued) 209
NEED FOR MORE EFFICIENT DRUG DISCOVERY AND DEVELOPMENT PROCESS 210
GROWTH IN PERSONALIZED MEDICINE 210
NEED FOR EARLY DETECTION OF CANCERS 211
AGING POPULATIONS 211
NEW DISCOVERIES IN GENOMICS AND PROTEOMICS 212
MINIATURIZATION OF BIOCHIPS 212
DECLINE IN GENETIC ANALYSIS COSTS 212
DISCOVERY OF GENE- AND SNP-DISEASE ASSOCIATIONS 213
Chapter-9: BIOCHIP MARKETS
GLOBAL BIOCHIP MARKET 214
TABLE 85 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 214
TABLE 86 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS) 215
MICROARRAY MARKETS 216
TABLE 87 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH 2014 ($ MILLIONS) 216
DNA MICROARRAY MARKETS 217
DNA MICROARRAY MARKET BY APPLICATION 217
TABLE 88 GLOBAL VALUE OF DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 217
DNA Microarray Market by Application (Continued) 218
FIGURE 28 ENTRIES TO MIRNA DATABASE, 2002–2009 (NUMBER) 219
TABLE 89 GLOBAL VALUE OF GENOTYPING DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 220
DNA MICROARRAY MARKET BY END-USE INDUSTRY 220
TABLE 90 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS) 221
DNA MICROARRAY MARKET BY FORMAT 222
TABLE 91 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT, THROUGH 2014 ($ MILLIONS) 222
BIOCHIPS DIAGNOSTICS MARKETS 223
BIOCHIPS DIAGNOSTIC MARKET BY APPLICATION 223
TABLE 92 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 224
Biochips Diagnostic Market by Application (Continued) 225
BIOCHIP DIAGNOSTICS MARKET BY BIOCHIP TYPE 226
TABLE 93 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS) 226
CANCER DIAGNOSTICS BIOCHIPS MARKET BY INDICATION 227
TABLE 94 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY INDICATION, THROUGH 2014 ($ MILLIONS) 227
Cancer Diagnostics Biochips Market … (Continued) 228
CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP TYPE 229
TABLE 95 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS) 229
TABLE 96 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 230
DIAGNOSTIC DNA MICROARRAYS MARKET BY ANALYSIS METHOD 231
TABLE 97 GLOBAL VALUE OF DIAGNOSTIC DNA MICROARRAYS BY ANALYSIS METHOD, THROUGH 2014 ($ MILLIONS) 231
Diagnostic DNA Microarrays Market … (Continued) 232
DIAGNOSTIC DNA MICROARRAYS MARKET BY DIAGNOSTIC FUNCTION 233
TABLE 98 GLOBAL VALUE OF DNA MICROARRAYS DIAGNOSTICS BY DIAGNOSTIC FUNCTION, THROUGH 2014 ($ MILLIONS) 233
DIAGNOSTIC PROTEIN MICROARRAY MARKET BY TECHNOLOGY 234
TABLE 99 GLOBAL VALUE OF PROTEIN MICROARRAY DIAGNOSTICS MARKET BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 235
PROTEIN MICROARRAYS MARKETS 236
PROTEIN MICROARRAYS MARKETS BY TECHNOLOGY 236
TABLE 100 GLOBAL VALUE OF PROTEIN MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 236
Protein Microarrays Markets by Technology (Continued) 237
PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT 238
TABLE 101 GLOBAL VALUE OF PROTEIN MICROARRAYS BY PRODUCT FORMAT, THROUGH 2014 ($ MILLIONS) 238
TABLE 102 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS 239
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY 240
TABLE 103 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS) 240
EMERGING MICROARRAYS MARKETS 241
EMERGING MICROARRAYS MARKET BY TECHNOLOGY 241
TABLE 104 GLOBAL VALUE OF EMERGING MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 241
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY 242
TABLE 105 GLOBAL VALUE OF EMERGING MICROARRAYS BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS) 243
LOAC MARKETS 243
VALUE OF LOAC DEVICES BY END-USE INDUSTRY 243
TABLE 106 GLOBAL VALUE OF LOAC DEVICES BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS) 244
Value of LOAC Devices by End-Use Industry (Continued) 245
Value of LOAC Devices by End-Use Industry (Continued) 246
Value of LOAC Devices by End-Use Industry (Continued) 247
LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION 248
TABLE 107 GLOBAL VALUE OF LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS) 249
LOAC Drug Discovery and Development … (Continued) 250
LOAC DIAGNOSTICS MARKET BY APPLICATION 251
TABLE 108 GLOBAL VALUE OF LOAC DEVICES DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS) 252
LOAC Diagnostics Market by Application (Continued) 253
BIOCHIPS GEOGRAPHIC MARKETS 254
GLOBAL VALUE OF BIOCHIPS PRODUCTS BY GEOGRAPHY 254
TABLE 109 GLOBAL VALUE OF BIOCHIP PRODUCTS BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 255
MICROARRAY GEOGRAPHICAL MARKETS 255
TABLE 110 GLOBAL VALUE OF DNA MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 256
TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 257
TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 257
LOAC GEOGRAPHICAL MARKETS 258
TABLE 113 GLOBAL VALUE OF LOAC BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 258
Chapter-10: INDUSTRY DYNAMICS
INTRODUCTION 259
RECENT ACQUISITIONS IN THE BIOCHIP INDUSTRY 259
TABLE 114 KEY ACQUISITIONS IN BIOCHIP INDUSTRY, 2007–2009 260
RECENT ACQUISITIONS IN THE BIOCHIP … (CONTINUED) 261
RECENT ACQUISITIONS IN THE BIOCHIP … (CONTINUED) 262
RECENT ACQUISITIONS IN THE BIOCHIP … (CONTINUED) 263
DNA MICROARRAYS COMPETITIVE LANDSCAPE 264
TABLE 115 LEADING DNA MICROARRAY SUPPLIERS 264
TABLE 115 (CONTINUED) 265
SOURCES OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS 265
SOURCES OF COMPETITIVE … (CONTINUED) 266
TABLE 116 DNA MICROARRAY AND SEQUENCING COMPETITOR STRENGTHS AND WEAKNESSES 267
NEXT GENERATION SEQUENCING COMPETITIVE LANDSCAPE 268
TABLE 117 NUMBER OF SECOND-GENERATION GENOME SEQUENCING INSTRUMENTS AT MAJOR SEQUENCING CENTERS, 2009 269
DIAGNOSTICS BIOCHIP STRATEGIC ALLIANCES 269
TABLE 118 BIOCHIP STRATEGIC ALLIANCES IN DIAGNOSTICS 270
DIAGNOSTICS BIOCHIP STRATEGIC … (CONTINUED) 271
PROTEIN MICROARRAY SUPPLIERS 272
TABLE 119 PROTEIN AND SPECIALTY MICROARRAY SUPPLIERS BY MICROARRAY TECHNOLOGY 272
LOAC COMPETITIVE LANDSCAPE 273
TABLE 120 LOAC COMPETITOR LANDSCAPE, BY COMPANY 273
TABLE 120 (CONTINUED) 274
TABLE 120 (CONTINUED) 275
Chapter-11: PATENTS
INTRODUCTION 276
BIOCHIP INDUSTRY PATENT STATUS 276
FIGURE 29 ANNUAL ISSUED DNA MICROARRAY PATENTS BY REGION, 2001–2009 (NUMBER) 277
FIGURE 30 ANNUAL ISSUED PROTEIN MICROARRAY PATENTS BY REGION, 2001–2009 (NUMBER OF PATENTS GRANTED) 278
FIGURE 31 ANNUAL ISSUED LOAC PATENTS BY GEOGRAPHY, 2001–2009 (NUMBER) 279
BIOCHIP COMPANY PATENT STATUS 280
TABLE 121 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED MICROARRAY COMPANIES (NUMBER) 280
FIGURE 32 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED MICROARRAY COMPANIES, BY REGION (NUMBER) 281
FIGURE 32 (CONTINUED) 282
TABLE 122 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED LOAC COMPANIES (NUMBER) 283
FIGURE 33 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED LOAC COMPANIES (NUMBER) 284
BIOCHIP PATENT LITIGATION STATUS 284
TABLE 123 STATUS OF LIGITATION ISSUES IN THE BIOCHIP INDUSTRY 285
INDIVIDUAL PATENT STATUS OF SELECTED BIOCHIP COMPANIES 285
AFFYMETRIX POSITION 285
COMBIMATRIX POSITION 286
ILLUMINA POSITION 287
CALIPER POSITION 287
ROCHE-NIMBLEGEN POSITION 288
Chapter-12: COMPANY PROFILES
20/20 GENE SYSTEMS, INC. 289
ABBOTT LABORATORIES 290
ABTECH SCIENTIFIC, INC. 290
ADVANCED LIQUID LOGIC, INC. 291
AFFYMETRIX, INC. 292
AFFYMETRIX, INC. (CONTINUED) 293
TABLE 124 AFFYMETRIX STRATEGIC ALLIANCES 294
AFFYMETRIX, INC. (CONTINUED) 295
AGENDIA BV 296
TABLE 125 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE 296
AGENDIA BV (CONTINUED) 297
AGILENT TECHNOLOGIES, INC. 298
AGILENT TECHNOLOGIES, INC. (CONTINUED) 299
TABLE 126 AGILENT ACQUISITIONS, 2007–2009 300
AGNITIO SCIENCE AND TECHNOLOGY 301
ALLEGRO DIAGNOSTICS, INC. 302
ALMAC GROUP, LTD. 302
APPLIED MICROARRAYS, INC. 303
APPLIED MICROARRAYS, INC. (CONTINUED) 304
ARRAYIT CORP. 305
ARRAYJET, LTD. 305
ARRAYON BIOTECHNOLOGY 306
ASPER BIOTECH 306
ASTERAND 306
AUSHON BIOSYSTEMS, INC. 307
AUTOGENOMICS, INC. 307
TABLE 127 AUTOGENOMICS MICROARRAY-BASED DIAGNOSTICS PIPELINE 308
AYANDA BIOSYSTEMS S.A. 308
BAYER AG 309
TABLE 128 CELL LYSATE MICROARRAYS VERSUS WESTERN BLOT 310
BECTON DICKINSON 311
BIACORE AB 311
BIOCARTIS S.A. 312
BIODOT, INC. 312
BIOLOC, LLC 312
BIOMICRO SYSTEMS, INC. 313
BIO-RAD LABORATORIES, INC. 313
BIOSITE, INC. 314
BIOTHERANOSTICS 315
BIOTRAY 315
BIOTROVE, INC. 316
BLUEGNOME, LTD. 316
BODITECH MED, INC. 317
CALIPER LIFE SCIENCES 317
CALIPER LIFE SCIENCES (CONTINUED) 318
CALIPER LIFE SCIENCES (CONTINUED) 319
CAPITALBIO CORP. 320
CAPITALBIO CORP. (CONTINUED) 321
CELLECTRICON AB 322
CELLIX, LTD. 322
CELL-KINETICS, LTD. 323
CEPHEID 324
TABLE 129 COMMERCIAL STATUS OF CEPHEID CLINICAL DIAGNOSTIC TESTS BASED ON XPERT AND SMARTCYCLER PLATFORMS 325
CEPHEID (CONTINUED) 326
CLAROS DIAGNOSTICS 327
CLONTECH LABORATORIES 328
COMBIMATRIX CORP. 329
TABLE 130 COMBIMATRIX DNA MICROARRAY PLATFORMS 329
TABLE 131 COMBIMATRIX DNA MICROARRAY-BASED LAUNCHED DIAGNOSTICS 330
COVENTOR, INC. 331
CRYSTAL VISION MICROSYSTEMS S.A. 331
CYCLOFLUIDIC 332
DEBIOTECH S.A. 332
DIAGENIC ASA 332
DIAGENIC ASA (CONTINUED) 333
TABLE 132 DIAGENIC PATENT PORTFOLIO 334
DIAGNOSWISS S.A. 334
DNAVISION S.A. 335
DYCONEX AG 336
ECOARRAY, INC. 337
EDEL THERAPEUTICS S.A. 337
EKSIGENT TECHNOLOGIES 338
EPIGEM, LTD. 338
EXIQON A/S 339
EXONHIT THERAPEUTICS S.A. 340
TABLE 133 EXONHIT'S SPLICE-ARRAY DIAGNOSTICS PIPELINE 340
EXONHIT THERAPEUTICS S.A. (CONTINUED) 341
FEBIT BIOTECH GMBH 342
FLUIDIGM CORP. 342
FLUIDIGM CORP. (CONTINUED) 343
FLUIGENT 344
FLUXION BIOSCIENCES INC. 344
GE HEALTHCARE LIFE SCIENCES, LTD. 344
GENETIX, LTD. 345
GENEWAVE S.A.S. 346
GENOMICS USA, INC. 347
GENPROBE, INC. 347
GENTEL BIOSCIENCES, INC. 348
GLYCOMINDS, LTD. 349
GRACE BIO-LABS, INC. 349
GREINER BIO-ONE GMBH 350
TABLE 134 GREINER BIO-ONE BIOCHIP-BASED DIAGNOSTICS PIPELINE 350
GYROS AB 351
HANDYLAB, INC. 352
HIGH THROUGHPUT GENOMICS, INC. 353
HOLOGIC, INC. 353
IBIDI GMBH 354
ICX TECHNOLOGIES 354
ILLUMINA, INC. 355
TABLE 135 ILLUMINA SEQUENCING TECHNOLOGY SPACE 356
IMMUCOR, INC. 357
INDEVR, INC. 358
INVERNESS MEDICAL INNOVATIONS, INC. 358
IRIS BIOTECHNOLOGIES 359
JOHNSON & JOHNSON AMIC AB 360
KINEXUS BIOINFORMATICS CORP. 361
LC SCIENCES 361
LIFE BIOSCIENCE, INC. 362
LIFE TECHNOLOGIES, INC. 363
LIFE TECHNOLOGIES, INC. (CONTINUED) 364
LUMINEX 365
TABLE 136 LUMINEX MDX PIPELINE 366
TABLE 137 LUMINEX PARTNER SUMMARY 367
MICRALYNE, INC. 368
MICROCHIPS, INC. 368
MICROFLUIDIC SYSTEMS, INC. 369
MICROLIQUID 370
MICRONICS, INC. 370
MICRONIT MICROFLUIDICS 371
MICROPLUMBERS MICROSCIENCES, LLC 371
MILLIPORE 372
MOBIDIAG, LTD. 372
MOLECULAR PROFILING INSTITUTE 373
NANOSPHERE 374
NANOSURFACE BIOSCIENCES 374
NUVERA BIOSCIENCES 375
OCIMUM BIOSOLUTIONS, LTD. 376
ORIGENE TECHNOLOGIES, INC. 376
OSMETECH MOLECULAR DIAGNOSTICS 377
OSMETECH MOLECULAR DIAGNOSTICS (CONTINUED) 378
OY JURILAB, LTD. 379
PAMGENE INTERNATIONAL B.V. 380
PANAGENE, INC. 380
PATHWORK DIAGNOSTICS 381
PEPSCAN PRESTO B.V. 382
PERKINELMER 382
PERKINELMER (CONTINUED) 383
PERLEGEN SCIENCES, INC. 384
PROMEGA CORP. 384
PROTAGEN AG 385
QUANTRX BIOMEDICAL CORP. 386
QUEST DIAGNOSTICS 387
RANDOX LABORATORIES, LTD. 388
TABLE 138 RANDOX BIOCHIPS ASSAYS PORTFOLIO 389
ROCHE LIFE SCIENCES 390
ROCHE LIFE SCIENCES (CONTINUED) 391
SEQUENOM, INC. 392
SEQUENOM, INC. (CONTINUED) 393
SCHOTT JENA GLASS GMBH 394
SIEMENS AG 395
SIGMA ALDRICH CORP. 395
TABLE 139 SIGMA ALDRICH ACQUISITIONS, 2006–2009 396
SIGNATURE GENOMIC LABORATORIES, LLC 397
SIRS-LAB GMBH 398
SPINX TECHNOLOGIES 398
SQI DIAGNOSTIC SYSTEMS 399
STMICROELECTRONICS 400
SUPERBIOCHIP LABORATORIES 401
SURMODICS, INC. 401
TESSARAE 402
THINXXS MICROTECHNOLOGY AG 402
TRANSLUME, INC. 403
VEREDUS LABORATORIES PTE, LTD. 403
VERENIUM CORP. 404
WASATCH MICROFLUIDICS 405
WEIDMAN PLASTICS TECHNOLOGIES 405
WETWARE CONCEPTS S.R.L. 406
XCEED MOLECULAR 406
XENOPORE 407
ZEPTOSENS AG 407
To order this report:
Biotechnology Industry: Global Biochip Markets: Microarrays and Lab-on-a-Chip
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article